Denali Therapeutics Inc (NASDAQ: DNLI) on Friday, plunged -7.90% from the previous trading day, before settling in for the closing price of $12.79. Within the past 52 weeks, DNLI’s price has moved between $12.05 and $33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 260.06% over the last five years. The company achieved an average annual earnings per share of -12.76%. With a float of $125.71 million, this company’s outstanding shares have now reached $142.63 million.
The firm has a total of 422 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Denali Therapeutics Inc is 13.43%, while institutional ownership is 88.02%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.03% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Denali Therapeutics Inc (DNLI) is currently performing well based on its current performance indicators. A quick ratio of 8.46 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.58, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.58 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Analysing the last 5-days average volume posted by the [Denali Therapeutics Inc, DNLI], we can find that recorded value of 2.63 million was better than the volume posted last year of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 32.59%. Additionally, its Average True Range was 1.20.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 2.05%, which indicates a significant decrease from 11.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.45% in the past 14 days, which was higher than the 72.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.07, while its 200-day Moving Average is $23.02. Now, the first resistance to watch is $12.50. This is followed by the second major resistance level at $13.21. The third major resistance level sits at $13.80. If the price goes on to break the first support level at $11.20, it is likely to go to the next support level at $10.61. Should the price break the second support level, the third support level stands at $9.90.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
Market capitalization of the company is 1.71 billion based on 145,215K outstanding shares. Right now, sales total 0 K and income totals -422,770 K. The company made 0 K in profit during its latest quarter, and -114,750 K in sales during its previous quarter.
